Los Angeles, USA, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Herpes Zoster Pipeline Report: Current Therapies, Emerging Drugs, and Treatment Outlook
Approximately 6+ key companies are developing therapies for Herpes Zoster treatment. Curevo Vaccine has its drug candidates in the most advanced stage (Phase I). An increase in the prevalence of the disease and an increase in the elderly population will lead to cutting-edge technological developments for the effective treatment of the herpes zoster.
DelveInsight’s “Herpes Zoster Pipeline Insight” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in the Herpes Zoster pipeline landscapes. It comprises Herpes Zoster pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Herpes Zoster therapeutics assessment by product type, stage, route of administration, and molecule type and highlights the inactive Herpes Zoster pipeline products.
Some of the key takeaways from the Herpes Zoster Pipeline Report
Get an overview of pipeline landscape @ Herpes Zoster Clinical Trials Analysis
Herpes Zoster, also known as Shingles, is a localized, blistering, and painful rash caused by the varicella-zoster virus’s reactivation (VZV). The first line of treatment for Herpes Zoster and the most widely used agents for zoster infection are antiviral agents such as Acyclovir, valacyclovir, and famciclovir.
Herpes Zoster Emerging Drugs
CRV-101 is an investigational adjuvanted subunit vaccine to indicate the Herpes Zoster prevention in older adults. It is a next-generation shingles vaccine candidate designed to maximize CMI protection by combining the gE protein antigen with its proprietary adjuvant. The vaccine is in Phase I clinical studies to prevent shingles in adults.
A varicella-zoster virus vaccine (EG HZ) is a non-live, recombinant subunit vaccine being developed by EyeGene to prevent herpes zoster caused by the varicella-zoster virus (VZV). The vaccine combines a recombinant antigen, glycoprotein E (VZVgE), and CIA09, an adjuvant system. A Phase I clinical trial evaluating the EG-HZ vaccine has been completed.
GLS-5100 is a DNA-based varicella-zoster virus vaccine encoding an antigen involved in virus latency. GLS-5100 induces no safety concerns and can be used in immunosuppressed persons. The vaccine is in the preclinical stage for the treatment of Herpes Zoster.
For further information, refer to the detailed report @ Herpes Zoster Pipeline Therapeutics
Scope of Herpes Zoster Pipeline Drug Insight
· Herpes Zoster Therapies Late-stage (Phase III) · Herpes Zoster Therapies Mid-stage (Phase II)· Herpes Zoster Therapies Early-stage (Phase I) · Herpes Zoster Preclinical stage and Discovery candidates · Discontinued and Inactive candidates
· Immunostimulants· Glycoprotein inhibitors· Immediate early protein inhibitors
· Gene therapy · Monoclonal Antibody · Small molecule · Peptides· Polymer
· Subretinal · Parenteral · Oral· Intravitreal· Topical
· Monotherapy· Combination· Mono/Combination
Key Questions regarding Current Herpes Zoster Treatment Landscape and Emerging Therapies Answered in the Pipeline Report
Table of Contents
Get a customized pipeline report @ Herpes Zoster Drugs Pipeline Report
Other Reports
Browse Blog Posts
About DelveInsightDelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.
